BiotechTube

S-217622

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Impairment

Conditions

Renal Impairment

Trial Timeline

Aug 10, 2022 → Apr 12, 2023

NCT ID
NCT05363215

About S-217622

S-217622 is a phase 1 stage product being developed by Shionogi for Renal Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT05363215. Target conditions include Renal Impairment.

What happened to similar drugs?

20 of 20 similar drugs in Renal Impairment were approved

Approved (20) Terminated (0) Active (0)
✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved
✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved
✅Tacrolimus, Prograf®Astellas PharmaApproved
✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved
✅Tacrolimus + CyclosporineAstellas PharmaApproved
✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05409911Phase 1Completed
NCT05363215Phase 1Completed

Competing Products

20 competing products in Renal Impairment

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
23
LY3473329Eli LillyPhase 1
29
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
35
LY3819469Eli LillyPhase 1
29
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
32
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
AGS-16C3FAstellas PharmaPhase 1
29
AGS-16M8FAstellas PharmaPhase 1
29
CP-461Astellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 3
40
YM178Astellas PharmaPhase 1
29
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
29
bixalomerAstellas PharmaPre-clinical
26